Newsroom

Patients with stage III melanoma were treated with nivolumab (anti-PD1) and relatlimab (anti-LAG-3) before surgery 87% of patients remained alive and 80% were disease free four years after treatment Nearly all patients whose tumors responded to treatment before surgery remained disease-free after four years Researchers found potential biomarkers that can highly predict which patients have better outcomes or are at high risk of recurrence...